From left to right: Dr Stefan Randl, Vice President of Research, Development & Innovation for Evonik Health Care, Paul Spencer, Head of Product Line Drug Delivery & Medical Device Solutions at Evonik’s Health Care, Dr Thomas Riermeier, Head of Evonik Health Care, Mary Gregory, Associate Assistant Deputy Minister, Ministry of Innovation, Science and Industry, Detlef Engler, Trade Commissioner and Senior Investment Councelor at Government of Canada, Johann-Caspar Gammelin, President of the Nutrition & Care division, The Honourable François-Philippe Champagne, Minister of Innovation, Science and Industry, Andreas Weichert, Envoy-Counsellor, Embassy of Canada in Germany, The Honourable Stéphane Dion, Ambassador to Germany and Special Envoy to the European Union and Europe.

Press release
Health Care
November 9, 2021

Evonik welcomes Canadian delegation to Darmstadt, Germany

Evonik met with a delegation of representatives from Canada at its site in Darmstadt yesterday.

  • Reconfirming Evonik’s innovation position in Canada and its contribution to fight COVID-19
  • Discussing competencies in lipid nanoparticles at Evonik’s Vancouver laboratories
  • Evaluating future collaboration opportunities


Darmstadt, Germany. Evonik met with a delegation of representatives from Canada at its site in Darmstadt yesterday. Among the delegation were the Canadian Minister of Innovation, Science and Industry, Honourable François-Philippe Champagne, and the Canadian Ambassador to Germany and Special Envoy to the European Union and Europe, Honourable Stéphane Dion.

“We were honored to welcome this delegation from Canada to Evonik Health Care. Much of the technical know-how and innovation leading to our success in lipids and lipid nanoparticles for mRNA therapeutics has been thanks to decades of experience at our laboratories in Vancouver,” said Johann-Caspar Gammelin, President of the Nutrition & Care division.

Evonik has sites in seven locations in Canada including its Vancouver Laboratories in British Columbia for lipid-based parenteral drug delivery which plays a pivotal role in the rapid development and application of novel mRNA therapeutics. Consequently, the Covid-19 pandemic has accelerated the portfolio of system solutions for advanced drug delivery at Evonik Health Care, which is part of the life sciences division Nutrition & Care.

“We didn’t choose the timing of this pandemic and we will not choose the timing of the next health crisis, but we can choose to be better prepared. Canada’s Biomanufacturing and Life Sciences Strategy will build on areas of Canadian strength, including mRNA technologies. A robust Canadian life sciences ecosystem with participants like Evonik will help accelerate scientific discoveries to address global health challenges,” said Honourable François-Philippe Champagne.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. About 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Nutrition & Care

The focus of the business of the Nutrition & Care division is on health and quality of life. It develops differentiated solutions for active pharmaceutical ingredients, medical devices, nutrition for humans and animals, personal care, cosmetics, and household cleaning. In these resilient end markets, the division generated sales of around three billion euros in 2020 with about 5,300 employees.


In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.